Study | Kumamoto study | UKPDS 33 | UKPDS 80 (post-UKPDS 33) | ACCORD | ADVANCE | VADT |
Population | 110 | 4209 | 3277 | 10,251 | 11,140 | 1791 |
Age (years) | 47-52 | 53 | 62 | 66 | 60 | |
BMI (kg/m2) | 19-21 | 28 | 32 | 28 | 31 | |
Complications | –/+ | –/+ | ++ | ++ | ++ | |
Disease duration (years) | 6-10 | 0 | 10 | 8 | 11.5 | |
Baseline A1C (%) | 8.9-9.4 | 7.1 | 8.3 | 7.5 | 9.4 | |
Post-trial A1C (intensive versus standard; %) | 7.1 versus 9.4 | 7.0 versus 7.9 | 6.3 versus 7.5 | 6.5 versus 7.3 | 7.0 versus 8.5 | |
Microvascular endpoints | ||||||
Retinopathy | 0.31 (0.13-0.76) ≥2-step cumulative change | 0.75 (0.60-0.98) Any microvascular outcome | 0.76 (0.64-0.89) Any microvascular outcome | 0.67 (0.51-0.87)* 3-step progression | 0.72 (0.44-1.17)* 3-step progression | 0.77 (0.58-1.02) 2-step progression |
Nephropathy | 0.30 (0.11-0.86) New or worsening nephropathy | 0.72 (0.61-0.84) Incident macroalbuminuria | 0.79 (0.66-0.93) New or worsening nephropathy | 0.65 (0.49-0.89) Any increase in albuminuria | ||
Neuropathy | 0.92 (0.86-0.99) Neuropathy (MNSI>2) | 0.99 (0.87-1.14) Any new neuropathy |
Do you want to add Medilib to your home screen?